Oyster Point Pharma, Inc. (OYST)


+0.18 (+2.57%)
Symbol OYST
Price $7.19
Beta 1.055
Volume Avg. 0.14M
Market Cap 192.918M
Shares () -
52 Week Range 3.46-19.98
1y Target Est -
DCF Unlevered OYST DCF ->
DCF Levered OYST LDCF ->
ROE -141.70% Strong Sell
ROA -74.77% Strong Sell
Operating Margin -
Debt / Equity 1235.82% Strong Buy
P/E -
P/B 17.85 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest OYST news

Dr. Jeffrey Nau
NASDAQ Global Select

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.